- Home
- ICON vs NCNA Comparison
ICON vs NCNA Comparison
Compare ICON & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- NCNA
- Stock Information
- Founded
- ICON 2023
- NCNA 1997
- Country
- ICON Greece
- NCNA United Kingdom
- Employees
- ICON N/A
- NCNA N/A
- Industry
- ICON
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- NCNA Health Care
- Exchange
- ICON Nasdaq
- NCNA Nasdaq
- Market Cap
- ICON 3.6M
- NCNA 3.4M
- IPO Year
- ICON 2024
- NCNA 2017
- Fundamental
- Price
- ICON $1.75
- NCNA $0.89
- Analyst Decision
- ICON Strong Buy
- NCNA Buy
- Analyst Count
- ICON 1
- NCNA 2
- Target Price
- ICON $280.00
- NCNA $25.00
- AVG Volume (30 Days)
- ICON 30.9M
- NCNA 117.7K
- Earning Date
- ICON 05-15-2025
- NCNA 05-15-2025
- Dividend Yield
- ICON 0.23%
- NCNA N/A
- EPS Growth
- ICON N/A
- NCNA N/A
- EPS
- ICON 12.11
- NCNA N/A
- Revenue
- ICON $4,810,000.00
- NCNA N/A
- Revenue This Year
- ICON $32.17
- NCNA N/A
- Revenue Next Year
- ICON $96.55
- NCNA N/A
- P/E Ratio
- ICON $0.15
- NCNA N/A
- Revenue Growth
- ICON 5.71
- NCNA N/A
- 52 Week Low
- ICON $1.60
- NCNA $0.69
- 52 Week High
- ICON $154.00
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- NCNA 48.84
- Support Level
- ICON N/A
- NCNA $0.81
- Resistance Level
- ICON N/A
- NCNA $1.34
- Average True Range (ATR)
- ICON 0.00
- NCNA 0.14
- MACD
- ICON 0.00
- NCNA 0.02
- Stochastic Oscillator
- ICON 0.00
- NCNA 30.66
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.